This may be one reason that vorinostat is efficacious in treating advanced MF and other hematologic malignancies [20,21], as suppression of CTLA-4 likely promotes a more robust immune response against malignant tissues [22]. The gene discussed is CTLA4; the disease is hematologic disorder.